Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Goldman Says Buy Brisol-Myers on Weakness

Goldman Sachs says investors should buy Bristol-Myers Squibb (BMY) shares on weakness.

Analyst James Kelly says the company's partner, ImClone Systems IMCL

, announced the FDA has not accepted its licensing application for Erbitux. He says the setback for one pipeline product could create an opportunity in BMY shares and would buy on weakness. He notes the application was based on small data set, and more data is being accumulated, so this should represent a delay, not a permanent derailment.

He notes he's assuming a one-year delay; moving Erbitux to '03 leaves his BMY $2.28 '02 EPS estimate unchanged, but '03 falls by $0.02 to $2.52. He expects volatility today, but would be aggressive near $50.

blog comments powered by Disqus